What makes us different? Read our Declaration of Journalistic Independence Home | About Natural News | Contact Us | Write for Natural News
placebo

Psych Drug Shocker: Antidepressant Drugs Work No Better than Placebo; Big Pharma Hoax Finally Exposed

Monday, February 25, 2008 by: Mike Adams (see all articles by this author) | Key concepts: placebo, depression and antidepressants

Want stories like this e-mailed to you? Click here for free email alerts

Email this article to a friend Printable Version

Personal Health Solutions from NaturalNews

Replace your toxic laundry detergent with natural laundry soap that grows on trees! (Popular solution!)
This top "underground" natural health newsletter brings you amazing new natural cures each month. Save $100!
How to treat and cure over 100 health conditions using little-known health secrets
How to halt type-2 diabetes with nutritional therapy - over 50% cure rate proven in studies
End cravings with this guide to natural appetite suppressants (Download edition available.)
How to blend nutritious meals in minutes with Adams' Superfood smoothie recipes (Delicious!)
Breakthrough LED lighting technology prevents global warming, saves 90% on your lighting bill

Browse more health books...
Shop our eco-friendly products...

All sales help fund NaturalNews operations.
(NaturalNews) The following is a groundbreaking report from the independent, honest medical journal PLoS Medicine (which accepts no advertising money from Big Pharma). The full study, with sources and attributions, can be found at http://medicine.plosjournals.org/perlse...

This study is sending shockwaves through the medical community. It finally reveals the Big Pharma hoax behind antidepressant drugs. Through fraudulent science and clever marketing, drug companies have managed to take a drug that works no better than placebo and turn it into a multi-billion dollar scam. But the truth is finally out: Taking Prozac is no more effective than taking a sugar pill! Hundreds of millions of consumers have been fooled by the quack science supporting modern pharmaceutical medicine. Read the study details below...

Editor's Summary:

Everyone feels miserable occasionally. But for some people -- those with depression -- these sad feelings last for months or years and interfere with daily life. Depression is a serious medical illness caused by imbalances in the brain chemicals that regulate mood. It affects one in six people at some time during their life, making them feel hopeless, worthless, unmotivated, even suicidal. Doctors measure the severity of depression using the "Hamilton Rating Scale of Depression" (HRSD), a 17–21 item questionnaire. The answers to each question are given a score and a total score for the questionnaire of more than 18 indicates severe depression. Mild depression is often treated with psychotherapy or talk therapy (for example, cognitive–behavioral therapy helps people to change negative ways of thinking and behaving). For more severe depression, current treatment is usually a combination of psychotherapy and an antidepressant drug, which is hypothesized to normalize the brain chemicals that affect mood. Antidepressants include "tricyclics," "monoamine oxidases," and "selective serotonin reuptake inhibitors" (SSRIs). SSRIs are the newest antidepressants and include fluoxetine, venlafaxine, nefazodone, and paroxetine.

Why Was This Study Done?

Although the US Food and Drug Administration (FDA), the UK National Institute for Health and Clinical Excellence (NICE), and other licensing authorities have approved SSRIs for the treatment of depression, some doubts remain about their clinical efficacy. Before an antidepressant is approved for use in patients, it must undergo clinical trials that compare its ability to improve the HRSD scores of patients with that of a placebo, a dummy tablet that contains no drug. Each individual trial provides some information about the new drug's effectiveness but additional information can be gained by combining the results of all the trials in a "meta-analysis," a statistical method for combining the results of many studies. A previously published meta-analysis of the published and unpublished trials on SSRIs submitted to the FDA during licensing has indicated that these drugs have only a marginal clinical benefit. On average, the SSRIs improved the HRSD score of patients by 1.8 points more than the placebo, whereas NICE has defined a significant clinical benefit for antidepressants as a drug–placebo difference in the improvement of the HRSD score of 3 points. However, average improvement scores may obscure beneficial effects between different groups of patient, so in the meta-analysis in this paper, the researchers investigated whether the baseline severity of depression affects antidepressant efficacy.

What Did the Researchers Do and Find?

The researchers obtained data on all the clinical trials submitted to the FDA for the licensing of fluoxetine, venlafaxine, nefazodone, and paroxetine. They then used meta-analytic techniques to investigate whether the initial severity of depression affected the HRSD improvement scores for the drug and placebo groups in these trials. They confirmed first that the overall effect of these new generation of antidepressants was below the recommended criteria for clinical significance. Then they showed that there was virtually no difference in the improvement scores for drug and placebo in patients with moderate depression and only a small and clinically insignificant difference among patients with very severe depression. The difference in improvement between the antidepressant and placebo reached clinical significance, however, in patients with initial HRSD scores of more than 28 -- that is, in the most severely depressed patients. Additional analyses indicated that the apparent clinical effectiveness of the antidepressants among these most severely depressed patients reflected a decreased responsiveness to placebo rather than an increased responsiveness to antidepressants.

What Do These Findings Mean?

These findings suggest that, compared with placebo, the new-generation antidepressants do not produce clinically significant improvements in depression in patients who initially have moderate or even very severe depression, but show significant effects only in the most severely depressed patients. The findings also show that the effect for these patients seems to be due to decreased responsiveness to placebo, rather than increased responsiveness to medication. Given these results, the researchers conclude that there is little reason to prescribe new-generation antidepressant medications to any but the most severely depressed patients unless alternative treatments have been ineffective. In addition, the finding that extremely depressed patients are less responsive to placebo than less severely depressed patients but have similar responses to antidepressants is a potentially important insight into how patients with depression respond to antidepressants and placebos that should be investigated further.

[Here is the abstract from the study]

Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration


Irving Kirsch, Brett J. Deacon, Tania B. Huedo-Medina, Alan Scoboria, Thomas J. Moore, Blair T. Johnson

Background

Meta-analyses of antidepressant medications have reported only modest benefits over placebo treatment, and when unpublished trial data are included, the benefit falls below accepted criteria for clinical significance. Yet, the efficacy of the antidepressants may also depend on the severity of initial depression scores. The purpose of this analysis is to establish the relation of baseline severity and antidepressant efficacy using a relevant dataset of published and unpublished clinical trials.

Methods and Findings

We obtained data on all clinical trials submitted to the US Food and Drug Administration (FDA) for the licensing of the four new-generation antidepressants for which full datasets were available. We then used meta-analytic techniques to assess linear and quadratic effects of initial severity on improvement scores for drug and placebo groups and on drug–placebo difference scores. Drug–placebo differences increased as a function of initial severity, rising from virtually no difference at moderate levels of initial depression to a relatively small difference for patients with very severe depression, reaching conventional criteria for clinical significance only for patients at the upper end of the very severely depressed category. Meta-regression analyses indicated that the relation of baseline severity and improvement was curvilinear in drug groups and showed a strong, negative linear component in placebo groups.

Conclusions

Drug–placebo differences in antidepressant efficacy increase as a function of baseline severity, but are relatively small even for severely depressed patients. The relationship between initial severity and antidepressant efficacy is attributable to decreased responsiveness to placebo among very severely depressed patients, rather than to increased responsiveness to medication.

Source: PLoS Medicine: http://medicine.plosjournals.org/perlse...

###

Related Articles

Psychiatric Drugs: Chemical Warfare on Humans - interview with Robert Whitaker

The placebo effect proves to be good medicine in twelve month study; mind/body medicine is more powerful than drugs and surgery

Do Antidepressants Cure or Create Abnormal Brain States? (PLoS Medicine)

The Top Ten Technologies: #9 Vibrational Medicine

New Understanding of the Role of Testosterone in Women

Popular Topics:

placebo, depression, antidepressants, Diabetes, High Blood Pressure, Breast cancer, Prostate cancer, Heart disease, Depression, High cholesterol, Osteoporosis, Vaccines, Autism, ADHD, Infertility, Weight loss, Cancer, Alzheimer's, Trans fats, Acrylamides, Fluoride, Mercury

Take Action: Support NaturalNews.com

Email this article to a friend

Share this article on: NewsVine | digg | del.icio.us

Permalink to this article: http://www.NaturalNews.com/022723.html

Reprinting this article: Non-commercial OK, cite NaturalNews.com with clickable link.

Receive our Natural Health Newsletter for FREE

Subscribe now (it's free!) to win. We randomly choose a subscriber each month to send $100 in eco-home products or a RealGoods.com gift certificate (our choice). Plus, you'll receive FREE news, articles and action alerts from NaturalNews.com editors and join over 800,000 monthly readers who report extraordinary health improvements after becoming a subscriber!
  • Receive breaking news alerts on natural health solutions, renewable energy, the environment, global warming and more.
  • Receive a free instant download of our $29 Secret Sources guide that reveals top sources for little-known health and diet solutions.
Your Email Address:
Free Subscription Code:
Enter the numbers you see:
100% free of charge. Unsubscribe anytime.
Absolutely no spam. We respect your email privacy.

Recommended Special Report:

Seven Words that can Change the World
by Joseph R. Simonetta

Read this special report now...

"Seven Words That Can Change the World reveals the astonishing, simple truths that have the power to forever transform our world for the better while freeing our minds from the enslavement of limiting beliefs. This is not a text for the simple-minded; it is a guiding philosophy for the mindful, intelligent few who are wise enough to seek out -- and recognize -- the higher simplicities of truly purposeful living." - Mike Adams, the Health Ranger, editor of NaturalNews.com

More on NaturalNews.com:

Streaming Health Ranger Videos
CounterThink Cartoons
FREE Special Reports
Podcasts

Also Posted Today

Review: Organic Food Bar Offers Exclusive Discount to Natural News Readers on Their Best Food Bars

Indole-3-Carbinol Nutrient in Broccoli Protects the Heart, Balances Cholesterol

The HPV Vaccine: Herd Immunity or Human Sacrifice?

Lead in Diabecon? An Ayurvedic Anti-Diabetes Herbal Complex Gets the Test

Scientists Agree That EMFs Pose a Threat to Your Health

Beat Disease With Juice Feasting!

NEW 6-CD audio set reveals amazing new protocol for reversing cancer, diabetes, obesity, heart disease and more. Click to learn more.

Own Health Ranger Report Podcasts on Audio CD

Own the first 8 Health Ranger Report audio programs on 6 CDs. Covers weight loss, ADHD, vaccinations, processed meats, bone health and more. Click to learn more.

Featured Videos

Short clip on Aspartame
A short clip on aspartame from the documentary All Jacked Up.
Click here to view now...

Exclusive video on Aspartame
The dangers of aspartame! Exclusive interview footage from Cori Brackett of Sweet Remedy.
Click here to view now...

Exclusive Footage from All Jacked Up!
See interview footage featuring the Health Ranger in the upcoming junk food film, All Jacked Up.
Click here to view now...

Drug Ad Parody
See the Health Ranger's satire parody of Merck's cholesterol drug ad.
Click here to view now...

Free Health Reports!

Amazon Herb Company review
The pH Nutrition Guide to Acid / Alkaline Balance
Pet Food Ingredients Revealed! (shocking)
Medicine From Fish
The Water Cure
The Healing Power of Sunlight and Vitamin D

Featured CounterThink Cartoons

Fidozac: Antidepressant Drugs for Dogs


New Warfare


When pharmacists tell the truth


Health Product Companies We Recommend

Read recommendations on supplement companies, health food manufacturers and personal care product makers that you can trust. Our 100% independent review list tells you who to trust and who to avoid in the natural health industry. Click to read.
This site is part of the Natural News Network © 2008 All Rights Reserved. Privacy | Terms All content posted on this site is commentary or opinion and is protected under Free Speech. Truth Publishing International, LTD. is not responsible for content written by contributing authors. Truth Publishing sells no health or nutritional products and earns no money from health product manufacturers or promoters. The information on this site is provided for educational and entertainment purposes only. It is not intended as a substitute for professional advice of any kind. Truth Publishing assumes no responsibility for the use or misuse of this material. Your use of this website indicates your agreement to these terms and those published here. All trademarks, registered trademarks and servicemarks mentioned on this site are the property of their respective owners.